TY - JOUR
T1 - Low serum magnesium is associated with faster decline in kidney function
T2 - The Dallas Heart Study experience
AU - Ferrè, Silvia
AU - Li, Xilong
AU - Adams-Huet, Beverley
AU - Maalouf, Naim M.
AU - Sakhaee, Khashayar
AU - Toto, Robert D.
AU - Moe, Orson W.
AU - Neyra, Javier A.
N1 - Funding Information:
Funding The Dallas Heart Study is supported by grant UL1TR001105 from the National Center for Advancing Translational Science of the National Institutes of Health. This work was also supported by the University of Texas Southwestern Medical Center O’Brien Kidney Research Center (P30-DK079328). Dr Ferrè was supported by the Charles and Jane Pak Center Innovative Research Support Award. Dr Neyra is currently supported by an Early Career Pilot Grant from the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant UL1TR001998.
Publisher Copyright:
© American Federation for Medical Research 2019. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2019/8/1
Y1 - 2019/8/1
N2 - Hypomagnesemia associates with inflammation and risk of diabetes and hypertension, which may contribute to kidney function decline. We hypothesized that low serum magnesium (SMg) levels independently associate with a significant decline in estimated glomerular filtration rate (eGFR). We analyzed SMg levels in 2056 participants from the Dallas Heart Study, a longitudinal, population-based, multiethnic, cohort study involving residents of Dallas County, Texas, USA. The primary study outcome was the change in eGFR using multivariable linear regression models adjusted for demographics, anthropometric and biochemical parameters, medications, C reactive protein levels, prevalent hypertension and diabetes. During a median follow-up of 7.0 years (25th, 75th percentile: 6.5, 7.6), the median decrease in eGFR was -0.71 (25th, 75th percentile: -2.43, +0.68) mL/min/1.73 m 2 per year in the entire cohort. In a fully adjusted model, the lowest SMg quintile (≤1.9 mg/dL or ≤0.8 mM) was associated with a -0.50 mL/min/1.73 m 2 per year drop in eGFR (95% CI -0.95 to -0.05; p=0.028) compared with the highest SMg quintile (≥2.3 mg/dL or ≥1.0 mM). Every 0.2 mg/dL (0.08 mM) decrease in SMg was associated with an eGFR decline of -0.23 mL/min/1.73 m 2 per year (95% CI -0.38 to -0.08; p=0.003), a decline that was more pronounced in participants with prevalent diabetes compared with patients without diabetes (-0.51 vs -0.18 mL/min/1.73 m 2 per year, respectively). In conclusion, low SMg was independently associated with eGFR decline. Further studies are needed to determine whether Mg repletion can ameliorate inflammation, lower blood pressure and serum glucose and ultimately prevent or retard kidney function decline.
AB - Hypomagnesemia associates with inflammation and risk of diabetes and hypertension, which may contribute to kidney function decline. We hypothesized that low serum magnesium (SMg) levels independently associate with a significant decline in estimated glomerular filtration rate (eGFR). We analyzed SMg levels in 2056 participants from the Dallas Heart Study, a longitudinal, population-based, multiethnic, cohort study involving residents of Dallas County, Texas, USA. The primary study outcome was the change in eGFR using multivariable linear regression models adjusted for demographics, anthropometric and biochemical parameters, medications, C reactive protein levels, prevalent hypertension and diabetes. During a median follow-up of 7.0 years (25th, 75th percentile: 6.5, 7.6), the median decrease in eGFR was -0.71 (25th, 75th percentile: -2.43, +0.68) mL/min/1.73 m 2 per year in the entire cohort. In a fully adjusted model, the lowest SMg quintile (≤1.9 mg/dL or ≤0.8 mM) was associated with a -0.50 mL/min/1.73 m 2 per year drop in eGFR (95% CI -0.95 to -0.05; p=0.028) compared with the highest SMg quintile (≥2.3 mg/dL or ≥1.0 mM). Every 0.2 mg/dL (0.08 mM) decrease in SMg was associated with an eGFR decline of -0.23 mL/min/1.73 m 2 per year (95% CI -0.38 to -0.08; p=0.003), a decline that was more pronounced in participants with prevalent diabetes compared with patients without diabetes (-0.51 vs -0.18 mL/min/1.73 m 2 per year, respectively). In conclusion, low SMg was independently associated with eGFR decline. Further studies are needed to determine whether Mg repletion can ameliorate inflammation, lower blood pressure and serum glucose and ultimately prevent or retard kidney function decline.
KW - chronic kidney disease
KW - diabetes mellitus
KW - hypertension
KW - hypomagnesemia
KW - magnesium
UR - http://www.scopus.com/inward/record.url?scp=85062356146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062356146&partnerID=8YFLogxK
U2 - 10.1136/jim-2018-000966
DO - 10.1136/jim-2018-000966
M3 - Article
C2 - 30826804
AN - SCOPUS:85062356146
SN - 1081-5589
VL - 67
SP - 987
EP - 994
JO - Journal of Investigative Medicine
JF - Journal of Investigative Medicine
IS - 6
ER -